Human eggs are some of the most patient cells in the body, lying dormant for decades until needed. A study published in The ...

The 26S proteasome degrades polyubiquitylated (polyUb) proteins by an ATP-dependent mechanism. Here we show that binding of model polyUb substrates to the 19S regulator of mammalian and yeast 26S ...

Scientists reveal a new immune cell mechanism where the proteasome produces antibacterial peptides, offering hope against infections and antibiotic resistance.

The proteasome inhibitors bortezomib, carfilzomib, and ixazomib are effective in treating all stages of multiple myeloma. Learn why.

The proteasome droplets also contain ubiquitin-tagged proteins and multiple interacting proteins, by which induce liquid-liquid phase separation of the proteasome for rapid degradation of unwanted ...

The typical job of the proteasome, the garbage disposal of the cell, is to grind down proteins into smaller bits and recycle some of those bits and parts.

The role of the regulatory (19S) proteasome particle has always been exclusively linked to its functioning in the proteasome complex, where it collaborates with the catalytic (20S) particle to ...

Scientists at Sanford Burnham Prebys have developed a clearer picture of how crucial machinery in the human cell's recycling process for obsolete and misshapen proteins—known as proteasomes ...

A new study finds that proteasomes—structures that reside in all cells in the body and typically break down damaged proteins—can produce peptides that attack bacterial infections. When ...

Three proteasome inhibitors (PIs) are approved for patients with multiple myeloma (MM): Bortezomib, a first-in class PI, fights both newly diagnosed and relapsed/refractory MM (RRMM); carfilzomib ...